Equities researchers at SunTrust assumed coverage on shares of Juno Therapeutics Inc (NASDAQ:JUNO) in a note issued to investors on Thursday, The Fly reports. The firm set a “buy” rating and a $50.00 price target on the biopharmaceutical company’s stock. SunTrust’s price objective would suggest a potential upside of 83.62% from the stock’s previous close.

Other large investors recently made changes to their positions in the company. Private Asset Management increased its stake in shares of Juno Therapeutics by 23.8% in the fourth quarter. Private Asset Management now owns 6,375 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 1,225 shares in the last quarter. Numeric Investors LLC bought a new stake in shares of Juno Therapeutics during the fourth quarter valued at $541,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Juno Therapeutics by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 130,233 shares of the biopharmaceutical company’s stock valued at $5,726,000 after buying an additional 6,872 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Juno Therapeutics by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 22,081 shares of the biopharmaceutical company’s stock valued at $971,000 after buying an additional 300 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Juno Therapeutics during the fourth quarter valued at $297,000.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down 1.27% on Thursday, hitting $27.23. 1,334,905 shares of the stock traded hands. Juno Therapeutics has a one year low of $26.32 and a one year high of $69.28. The company’s market cap is $2.74 billion. The stock has a 50 day moving average of $38.29 and a 200 day moving average of $44.41.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.12. The business earned $1.60 million during the quarter, compared to the consensus estimate of $6.41 million. Equities analysts anticipate that Juno Therapeutics will post ($1.66) earnings per share for the current year.

In other Juno Therapeutics news, General Counsel Bernard J. Cassidy sold 3,200 shares of the stock in a transaction dated Thursday, November 19th. The stock was sold at an average price of $52.97, for a total transaction of $169,504.00. Following the sale, the general counsel now directly owns 71,200 shares of the company’s stock, valued at approximately $3,771,464. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $49.51, for a total value of $594,120.00. Following the sale, the director now directly owns 930,499 shares in the company, valued at $46,069,005.49. The disclosure for this sale can be found here.

A number of other analysts have also weighed in on the company. JPMorgan Chase & Co. restated an “overweight” rating and set a $69.00 target price on shares of Juno Therapeutics in a report on Wednesday, January 13th. FBR & Co. reiterated a “buy” rating and set a $73.00 price objective on shares of Juno Therapeutics in a report on Monday, January 11th. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “strong-buy” rating and set a $51.00 price objective for the company in a report on Monday, January 4th. Standpoint Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 15th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Juno Therapeutics in a report on Monday, November 30th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Juno Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $59.38.

Juno Therapeutics, Inc. (NASDAQ:JUNO) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

12 Month Chart for NASDAQ:JUNO

The Fly

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.